EBS - EBS エマ―ジェント・バイオソリュ―ションズ （）

https://www.investing.com/news/assorted/emergent-biosolutions-receives-contract-modification-from-hhs-for-smallpox-vaccine-432SI-3093793

In the last trading session, 1.0 million shares of the Emergent BioSolutions Inc. (NYSE:EBS) were traded, and its beta was 0.93. Most recently the company’s share price was $8.57, and it changed around $0.4 or 4.90% from the last close, which brings the market valuation of the company to $457.21M. EBS currently trades at a … Emergent BioSolutions Inc. (NYSE: EBS) Stock Forecast: Bullish Signals Pointing To $55.00 In 2023 Read More »

The FDA has approved Indivior PLC''s (OTC: INVVY ) Opvee (nalmefene) nasal spray for the emergency treatment of opioid overdose in adults and pediatric patients aged 12 years and older. Indivior added the product to its kitty when it acquired Opiant Pharmaceuticals Inc for 20.00 per share in cash, plus contingent value rights of up to $8.00 per share . In March, the FDA approved Emergent BioSolutions Inc''s (NYSE: EBS ) Narcan, 4 milligrams (mg) naloxone hydrochloride … Full story available on Benzinga.com

WASHINGTON (AP) — U.S. health regulators on Monday approved a new easy-to-use version of a medication to reverse overdoses caused by fentanyl and other opioids driving the nation’s drug crisis . Opvee is similar to naloxone, the life-saving drug that has been used for decades to quickly counter overdoses of heroin, fentanyl and prescription painkillers. Both work by blocking the effects of opioids in the brain, which can restore normal breathing and blood pressure in people who have recently overdosed. The Food and Drug Administration endorsed Opvee, a nasal spray update of the drug nalmefene, which was first approved as an injection in the mid-1990s but later removed from the market due to low sales. Naloxone comes as both a nasal spray and injection. It’s not immediately clear how the new drug will be used differently compared to naloxone, and some experts see potential downsides to its longer-acting effect. The drug will be available via prescription and is approved for patients 12 and older.

https://www.investing.com/news/pro/emergent-biosolutions-inc-receives-investment-bank-analyst-rating-update-3086706

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post TPI Composites, Inc. (NASDAQ:TPIC), Emergent BioSolutions Inc. (NYSE:EBS) – Tiling stocks appeared first on Stocks Equity .

It''s not a good day for investors when their company reports a shocking plunge into the red.

https://www.investing.com/news/pro/emergent-biosolutions-pt-lowered-to-21-at-singular-research-432SI-3017426

The following slide deck was published by Emergent BioSolutions Inc.

Emergent BioSolutions Inc. (NYSE:NYSE:EBS) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ETCompany ParticipantsBob Burrows - Vice President, Investor RelationsBob Kramer -…

During the last session, Emergent BioSolutions Inc. (NYSE:EBS)’s traded shares were 0.78 million, with the beta value of the company hitting 1.02. At the end of the trading day, the stock’s price was $32.76, reflecting an intraday gain of 1.30% or $0.42. The 52-week high for the EBS share is $68.03, that puts it down … After A 19.47% Jump In The Last Week, Does Emergent BioSolutions Inc. (NYSE: EBS) Still Make Sense To Buy? Read More »

DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA ® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent BioSolutions, Inc. (Emergent).

Emergent BioSolutions Inc. undefined said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax…

Emergent BioSolutions (EBS) announced on Friday that the FDA accepted its Biologics License Application ((BLA)) for the investigational anthrax vaccine AV7909 with a Prescription Drug…

Emergent BioSolutions Inc. said Friday the U.S. Food and Drug Administration has accepted for review its application for approval of its anthrax vaccine. Dubbed AV7909, the vaccine is aimed at people aged 18 through 65 years who have been exposed to anthrax for use along with recommended antibacterial drugs. A decision is expected by April of 2023. "As we progress toward licensure of AV7909, which is designed to follow a two-dose immunization schedule and to elicit a faster immune response, we redouble our efforts to support the government''s overall preparedness and response strategy for large-scale emergencies involving anthrax and other threats to public health," said Kelly Warfield, Emergent senior vice president for R&D, in a statement. The company has submitted data from a phase 3 clinical trial of the vaccine, as well as from a phase 2 trial. Emergent shares were down 3% premarket and have fallen 26% in the year to date, while the s&P500 has fallen 20%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move.